Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
James Condulis's Stock Ratings
Stifel Analyst
James Condulis is an analyst at Stifel. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 12/17/2025
Updated: Dec 17, 2025
Overall Average Return
17.3%
Smart Score
Overall Average Return Percentile
72nd
Number of Ratings
9
| Buy Now | Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 12/16/2025 | NAMS | Buy Now | NewAmsterdam Pharma Co | $34.16 | 46.37% | $44 → $50 | Maintains | Buy | Get Alert | |
| 12/05/2025 | XFOR | Buy Now | X4 Pharmaceuticals | $3.71 | 169.54% | $7.5 → $10 | Maintains | Buy | Get Alert | |
| 09/29/2025 | AARD | Buy Now | Aardvark Therapeutics | $13.92 | 72.41% | → $24 | Initiates | → Buy | Get Alert | |
| 09/02/2025 | CYTK | Buy Now | Cytokinetics | $62.27 | 54.17% | $87 → $96 | Maintains | Buy | Get Alert | |
| 06/10/2025 | NAMS | Buy Now | NewAmsterdam Pharma Co | $34.16 | 28.81% | → $44 | Initiates | → Buy | Get Alert | |
| 03/28/2025 | SLNO | Buy Now | Soleno Therapeutics | $49.50 | 118.18% | $74 → $108 | Maintains | Buy | Get Alert | |
| 03/05/2025 | SLNO | Buy Now | Soleno Therapeutics | $49.50 | 49.49% | → $74 | Reinstates | → Buy | Get Alert | |
| 01/22/2025 | CYTK | Buy Now | Cytokinetics | $62.27 | 28.47% | → $80 | Initiates | → Buy | Get Alert | |
| 01/22/2025 | EWTX | Buy Now | Edgewise Therapeutics | $22.59 | 32.8% | → $30 | Initiates | → Hold | Get Alert |
Market Resources
Trading Tools & Education
- Benzinga Pro Trading Platform
- Options Trading Strategies and News
- Stock Market Trading Ideas and Analysis
- Technical Analysis Charts and Indicators
- Fundamental Analysis and Valuation
- Day Trading Guides and Strategies
- Live Investors Events
- Pre market Stock Analysis and News
- Cryptocurrency Market Analysis and News
Ring the Bell
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.
© 2025 Benzinga | All Rights Reserved